Transdermal oestrogene application a contraindication in therapy of endometriosis with Gonadotropin-Releasing Hormon analogues

Rosen A, A. Rosen, Anders Rosén, Michael Klein, M Klein, Klein M, Beck A, Adolf Beck, A Beck
Klinische Wochenschrift · 1990 · vol. 68(10) , pp. 537 · doi:10.1007/bf01648254 · PMID:2197496 · W1995652406
article OA: closed CC0 ⤵ 1 in-corpus citation
Full text JSON View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite+body, 2026-06-09 ⓘ

This paper discusses the contraindication of transdermal estrogen application during therapy for endometriosis with Gonadotropin-Releasing Hormone analogues.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-12 · read from full text ⓘ

This short paper discusses a reported contraindication relevant to using GnRH analogues for endometriosis treatment, focusing on transdermal oestrogen application. It frames the issue in the context of hormonal therapy for endometriosis, where suppression of ovarian steroid production is a key therapeutic concept, and where introducing oestrogen via a transdermal route would be expected to counteract that effect. The limitation is that the provided text contains only bibliographic and citation metadata rather than detailed study methods or results, so the specific evidence base for the stated contraindication is not described here. This paper is centrally about endometriosis — specifically the compatibility/contraindication of transdermal oestrogen use when treating endometriosis with GnRH analogues.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Full text 1,247 characters · extracted from oa-doi-fallback · click to expand
References Barbieri RL (1988) New therapy for endometriosis. N Engl J Med 318:512–514 Maouris P (1989) A new treatment for Endometriosis. The Lancet 1:1017–1018 Matta WH, Shaw RW, Hesp R, Katz D (1987) Hypogonadism induced by hormone relesing hormone agonist analogues: effects on bone density in premenopausal women. Br Med J 294:1523 Meldrum DR, Chan RJ, Lu J, Vale W, Rivier J, Judd HL (1982) “Medical oophorectomy” using a long-acting GnRH agonist — a possible new approch to the treatment of endometriosis. J Clin Endocrinol Metab 54:1081 DiZerega GS, Barber DL, Hodgen GD (1980) Enometriosis: role of ovarian steroids in initiation, maintence and suppresion. Fertil Steril 33:649–653 Roddick JW, Conkey G, Jacobs EJ (1960) The hormonal response of enodometrotic implants and its relationship to symptomatology. Am J Obstet Gynecol 79:1173 Author information Authors and Affiliations Rights and permissions About this article Cite this article Rosen, A., Klein, M. & Beck, A. Transdermal oestrogene application a contraindication in therapy of endometriosis with Gonadotropin-Releasing Hormon analogues. Klin Wochenschr 68, 537 (1990). https://doi.org/10.1007/BF01648254 Received: Accepted: Issue date: DOI: https://doi.org/10.1007/BF01648254

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosis

MeSH descriptors

Endometriosis Estrogen Replacement Therapy Gonadotropin-Releasing Hormone Uterine Neoplasms Administration, Cutaneous Combined Modality Therapy Endometriosis Estrogen Replacement Therapy Female Gonadotropin-Releasing Hormone Gonadotropin-Releasing Hormone Humans Uterine Neoplasms

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (7)

Cited by (1)

Source provenance

europepmc
last seen: 2026-08-14T06:11:53.302379+00:00
openalex
last seen: 2026-06-04T00:00:01.174412+00:00
pubmed
last seen: 2026-05-13T22:12:10.587122+00:00
License: CC0 · commercial use OK